AI In Cardiology Market Drive US$ 40.5 Billion Growth By 2033

Introduction

Global AI In Cardiology Market was valued at the US$ 1.5 Billion in 2023 and is projected to reach a substantial growth of the US$ 40.5 Billion by 2033, with a CAGR of 39.4%. In 2023, North America led the market, achieving over 60.1% share with a revenue of US$ 0.9 Billion.

This remarkable growth is attributed to advancements in AI technology and the rising prevalence of cardiovascular diseases. These trends underscore the demand for innovative diagnostic and treatment solutions in cardiology.

Recent breakthroughs have highlighted AI’s transformative potential in cardiology. AI-powered cardiac diagnostics, such as automated image classification, have demonstrated exceptional accuracy, even rivaling human expertise in detecting arrhythmias. Regulatory agencies like the FDA have approved several AI-based technologies, including the AI ECG Tracker by Shenzhen Carewell Electronics and Apple Inc.’s ECG 2.0 App, paving the way for improved cardiovascular disease assessment. These approvals mark a significant step toward integrating AI into cardiovascular care, enabling faster and more precise patient outcomes by complementing, not replacing, human practitioners.

The market’s expansion is further driven by the increasing burden of cardiovascular diseases. Globally, 1.28 billion adults suffer from hypertension, a key risk factor for heart disease, with the majority residing in low- and middle-income countries. The rising demand for advanced diagnostic and treatment technologies positions AI as a critical tool in managing cardiovascular health and improving patient care.

In a notable development, Cardiovascular Associates of America (CVAUSA), managed by Webster Equity Partners, recently acquired Shore Heart Group (SHG), a New Jersey-based practice. With seven locations and a team of 23 cardiologists, this acquisition enhances CVAUSA’s network to over 80 locations in New Jersey, strengthening its cardiology services across multiple subspecialties. This strategic move aligns with CVAUSA’s mission to advance cardiac care through partnerships and expansions, reflecting the growing emphasis on collaborative healthcare delivery.

Key Takeaways

• The AI In Cardiology Market was valued at US$ 1.5 Billion in 2023 and is projected to reach an impressive US$ 40.5 Billion by 2033, exhibiting a remarkable CAGR of 39.4% during the forecast period.
• Software components dominated the market, with a substantial share of 61.3% in 2023, and are expected to maintain their dominance with a promising CAGR of 36.4%.
• Coronary artery disease holds a significant portion of the market with a revenue share of 54.6% in 2023, indicating a high demand for AI solutions in this application.
• North America leads the market with an impressive 60.1% market share in 2023, followed by Asia-Pacific, which is anticipated to witness the fastest growth due to improved healthcare infrastructure and rising incidences of cardiovascular conditions.
• Approximately 86.4% of people globally suffer from heart attacks and strokes, resulting in an average of USD 17.9 million deaths annually due to cardiovascular diseases.
• The rising prevalence of cardiovascular illnesses, such as stroke and heart disease, is a key driver for the market growth, with coronary heart disease being the most common type leading to approximately 375,476 mortality rates worldwide.
• Major market players such as Cleerly, Inc., DiA Imaging analysis, and Arterys Inc. are focusing on product strategies through acquisitions and mergers to introduce highly advanced AI technology in the cardiology market.

AI in Cardiology Key Statistics and Insights

• Accelerating Heart Attack Care: An AI algorithm tested on over 43,000 patients reduced the time from ECG to treatment in the cath lab by nearly 9 minutes, improving response times for heart attack care.
• Predicting Heart Failure Worsening: The AI-powered smartphone app HearO successfully predicted worsening heart failure conditions in 76% of patients, providing warnings approximately one month before hospitalization.
• Reducing False Alerts: Medtronic’s LINQ II ICM device, equipped with AI, decreased incorrect atrial fibrillation alerts by over 91%, saving physicians approximately 400 hours annually.
• Valvular Heart Disease Detection: Eko Health’s AI technology, integrated with a digital stethoscope, demonstrated 94.1% sensitivity and 84.5% specificity in detecting valvular heart disease during a study involving 369 patients.
• Cardiomyopathy in Pregnancy: In a study of nearly 1,200 women in Nigeria, AI doubled the detection rate of cardiomyopathy during and after pregnancy compared to traditional care methods.
• Market Growth Projections: The AI in Cardiology market is projected to surpass USD 40 billion by 2033, reflecting the sector’s rapid expansion.
• Accuracy in Echocardiograms: In evaluating 3,495 echocardiogram studies, AI outperformed sonographers, requiring cardiologists to make significantly fewer corrections to its assessments.
• Enhanced Cardiovascular Predictions: Research presented at the American Heart Association’s sessions highlighted AI’s ability to predict cardiovascular events and detect heart valve disease more effectively than traditional methods.
• AI and Digital Stethoscope: AI’s analysis of digital stethoscope sound data identified 94.1% of heart valve disease cases, outperforming standard detection methods.
• Risk Prediction from Eye Images: AI analysis of retinal images accurately predicted cardiovascular disease risks in individuals with prediabetes and Type 2 diabetes, showcasing its diverse applications in healthcare.

Diagnostic and Predictive Analytics

• ECG Interpretation and Arrhythmia Detection: AI has revolutionized electrocardiography (ECG) by automating interpretation and detecting subtle anomalies often missed by human experts. It excels in identifying arrhythmias, matching cardiologists’ diagnostic accuracy and enabling early interventions for atrial fibrillation and STEMI (ST-Elevation Myocardial Infarction).
• Heart Failure Monitoring: Advanced AI models predict the risk of heart failure readmissions by analyzing clinical and social factors with high precision. This targeted approach helps prevent avoidable hospitalizations and enhances patient outcomes.
• Voice Analysis for Heart Failure: AI-driven software analyzes changes in a patient’s voice, offering a non-invasive early warning system for worsening heart failure symptoms. This innovation improves outpatient care and reduces hospital readmissions.

Imaging and Analysis

• Plaque Detection in Cardiac CT Imaging: Deep learning algorithms accurately identify calcified plaques in arteries from CT scans, supporting early diagnosis and treatment of conditions leading to heart attacks and strokes.
• Automated Imaging Interpretation: AI enhances the speed and precision of cardiac CT angiogram analysis by identifying high-risk plaques and quantifying disease progression, far surpassing manual review methods.

rational Efficiency and Patient Care

• Reducing False Alerts from Cardiac Monitors: AI-powered models minimize false alerts from insertable cardiac monitors, saving healthcare professionals hundreds of hours annually while improving overall patient management.
• Digital Stethoscopes for Valvular Heart Disease: AI-enabled digital stethoscopes achieve high sensitivity and specificity in detecting valvular heart disease. This innovation streamlines primary care evaluations and reduces costs associated with delayed or missed diagnoses.

Recent Developments in AI in Cardiology

• Algorithm Innovation at Smidt Heart Institute, Cedars-Sinai: Researchers have developed a cutting-edge algorithm aimed at enhancing cardiovascular care, marking a significant advancement in AI applications within cardiology.
• Expanding Global Access with AI – UCSF Cardiology: The University of California, San Francisco (UCSF) has showcased AI’s ability to democratize clinical expertise worldwide. By analyzing fetal echocardiograms, AI is improving prenatal congenital heart disease diagnoses, breaking geographical barriers in specialized care delivery.
• Predictive Analytics and Operational Efficiency: The cardiology community recognizes AI’s role in transforming healthcare through predictive analytics. These technologies enable early disease detection and intervention, reducing hospitalizations, enhancing care quality, and lowering healthcare costs.
• AI’s Role in Post-Pandemic Medicine: The COVID-19 pandemic has accelerated AI research, spotlighting its importance in disease prediction, precision medicine, and rapid adaptation to emerging health challenges. This has opened new opportunities for early intervention and prevention strategies in cardiology.
• Balancing AI and the Human Element in Cardiology: While AI revolutionizes cardiology, it is widely agreed that its role is to augment rather than replace human expertise. By automating routine tasks, AI empowers healthcare professionals to dedicate more time to patient care, ensuring that technology enhances the human touch in medicine.

Key Players Analysis in AI-Driven Cardiology

• Cleerly, Inc.: Cleerly, Inc. is revolutionizing the diagnosis and management of coronary artery disease (CAD) through AI-powered coronary computed tomography angiography (CCTA) image analysis. Their platform excels in detecting and quantitatively assessing atherosclerosis (plaque buildup), offering precision far beyond traditional diagnostic methods. By delivering tailored treatment plans, Cleerly enhances patient outcomes and redefines the standards of cardiovascular care.
• DiA Imaging Analysis: DiA Imaging Analysis has positioned itself as a leader in AI-driven ultrasound analysis, particularly in cardiology. Using advanced deep learning and pattern recognition, their FDA-cleared software, such as LVivo IQS, provides real-time feedback on echocardiography image quality. This ensures accurate diagnoses and supports clinicians across diverse experience levels. Philips: recently acquired DiA Imaging Analysis, integrating its solutions to automate and simplify echo ultrasound exams. This strategic move by Philips aims to expand access to AI-enhanced cardiac imaging globally, aligning with its mission to advance cardiology technologies.
• Arterys Inc. (Now Part of Tempus): Arterys Inc. has pioneered AI-powered medical imaging solutions, seamlessly integrating applications into PACS and EHR workflows. Their Cardio AIMR platform, a web-based cardiac MR image analysis tool, leverages deep learning and cloud computing to enhance diagnostic accuracy and radiologist efficiency.
• The acquisition by Tempus, a leader in precision medicine, strengthens Arterys’ capabilities, creating a comprehensive, data-driven patient care model. This integration ensures actionable insights from imaging, improving the overall diagnostic and treatment process.
• CardiAI: Founded by Dr. Anmol Kapoor in 2018, CardiAI is at the forefront of AI innovations in cardiology. The company’s work spans clinical research, mobile healthcare advancements, and the development of medical devices. Notably, CardiAI applies machine learning to Holter monitor data, enabling early detection of arrhythmias and other cardiac conditions with improved accuracy. In collaboration with Carleton University, CardiAI is developing EG-FET biosensor technology, transforming point-of-care diagnostics by detecting critical biomarkers in saliva and blood. Additionally, their home-testing kits for heart and kidney health empower patients with accessible healthcare solutions, particularly in remote regions. CardiAI’s holistic approach enhances diagnostic efficiency and democratizes access to critical healthcare resources.

Conclusion

The integration of AI in cardiology has revolutionized diagnostic precision, treatment efficacy, and patient care. With advancements like automated imaging, predictive analytics, and early detection tools, AI demonstrates its transformative potential in addressing the global cardiovascular disease burden.

The market, valued at USD 1.5 billion in 2023, is projected to reach USD 40.5 billion by 2033, driven by rising disease prevalence and increasing adoption of AI technologies. Strategic partnerships and innovative solutions by key players underscore the rapid growth in this sector. While AI enhances efficiency, its role remains complementary to human expertise, ensuring improved healthcare delivery worldwide.

Discuss your needs with our analyst

Please share your requirements with more details so our analyst can check if they can solve your problem(s)

Request a Sample Download PDF